Principal Financial Group Inc Fate Therapeutics Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$3.26 - $7.08 $33,278 - $72,272	-10,208 Reduced 42.75%	13,668 $44,000
Q1 2024 Apr 29, 2024	SELL	$3.54 - $8.35 $10,304 - $24,306	-2,911 Reduced 10.87%	23,876 $175,000
Q4 2023 Feb 07, 2024	SELL	$1.65 - $3.94 $2,879 - $6,875	-1,745 Reduced 6.12%	26,787 $100,000
Q3 2023 Nov 02, 2023	BUY	$2.02 - $5.04 $5,851 - $14,600	2,897 Added 11.3%	28,532 $60,000
Q2 2023 Aug 07, 2023	BUY	$4.76 - $6.59 $12,780 - $17,694	2,685 Added 11.7%	25,635 $122,000
Q1 2023 May 09, 2023	SELL	$4.24 - $11.12 $7,275 - $19,081	-1,716 Reduced 6.96%	22,950 $130,000
Q4 2022 Feb 09, 2023	BUY	$9.86 - $23.83 $13,961 - $33,743	1,416 Added 6.09%	24,666 $248,000
Q3 2022 Nov 09, 2022	SELL	$21.04 - $36.06 $9,783 - $16,767	-465 Reduced 1.96%	23,250 $521,000
Q2 2022 Aug 10, 2022	SELL	$17.78 - $42.39 $36,502 - $87,026	-2,053 Reduced 7.97%	23,715 $588,000
Q1 2022 May 09, 2022	SELL	$29.67 - $60.28 $1.3 Million - $2.65 Million	-43,891 Reduced 63.01%	25,768 $999,000
Q4 2021 Feb 09, 2022	SELL	$47.84 - $64.34 $507,343 - $682,325	-10,605 Reduced 13.21%	69,659 $4.08 Million
Q3 2021 Nov 09, 2021	SELL	$59.27 - $95.73 $5.08 Million - $8.2 Million	-85,670 Reduced 51.63%	80,264 $4.76 Million
Q2 2021 Aug 10, 2021	SELL	$67.25 - $92.52 $3.2 Million - $4.41 Million	-47,652 Reduced 22.31%	165,934 $14.4 Million
Q1 2021 May 10, 2021	BUY	$72.16 - $117.4 $12.8 Million - $20.8 Million	177,510 Added 492.04%	213,586 $17.6 Million
Q4 2020 Feb 08, 2021	BUY	$38.09 - $100.95 $351,456 - $931,465	9,227 Added 34.37%	36,076 $3.28 Million
Q3 2020 Nov 06, 2020	BUY	$30.41 - $40.5 $2,098 - $2,794	69 Added 0.26%	26,849 $1.07 Million
Q2 2020 Aug 05, 2020	BUY	$20.21 - $35.23 $339,851 - $592,427	16,816 Added 168.77%	26,780 $919,000
Q1 2020 May 12, 2020	BUY	$17.28 - $31.88 $172,177 - $317,652	9,964 New	9,964 $221,000
Q4 2019 Feb 05, 2020	SELL	$13.39 - $20.73 $136,912 - $211,964	-10,225 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$15.47 - $22.5 $4,826 - $7,020	312 Added 3.15%	10,225 $159,000
Q2 2019 Aug 12, 2019	BUY	$15.61 - $20.44 $154,741 - $202,621	9,913 New	9,913 $201,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account